logo
Tempur-Pedic Adjustable Power Base Review: A Premium, Supportive Model

Tempur-Pedic Adjustable Power Base Review: A Premium, Supportive Model

Forbes14-07-2025
While the right mattress for your needs is crucial for a good night's rest, placing it atop an adjustable base can also be a game-changer for your sleep quality. A bed that elevates at the head and foot can be particularly beneficial for those who wake up with chronic pain, anyone who experiences reflux at night or people who regularly snore (and/or who share the bed with a snorer). I've been using the Tempur-Pedic Tempur-Ergo Adjustable Power Base for over three months now, and can attest to its value in helping me fall asleep more comfortably as well as minimizing my husband's snoring. In this Tempur-Pedic adjustable base review, I cover the bed's pros and cons as well as the types of sleepers who might benefit most from its use.
The Tempur-Pedic Tempur-Ergo Adjustable Base has a sturdy and supportive design at a competitive ... More price. ILLUSTRATION: FORBES / PHOTO: TEMPUR-PEDIC
We named the Tempur-Ergo Adjustable Power Base the best adjustable bed overall , thanks to its host of handy features at a competitive price. Tempur-Pedic has been a pioneer in foam mattress technology for decades (see our guide to the best Tempur-Pedic mattresses for more details), and the brand's high-quality mattresses are regularly regarded as solid options for those looking for pressure relief and strong motion isolation. Its suite of adjustable beds has, unsurprisingly, also garnered high praise, with four options available—ranging in price from $999 to $2,599 for a queen size, depending on how advanced the base is. The Tempur-Ergo Adjustable Power Base is a step above the classic model (the Ease Power Base ), with several more features, which I go into detail on below.
Forbes Vetted
Forbes Vetted ratings are based on thorough evaluations by our editorial team to help you choose the best products with confidence.
Size options: Twin XL, full, queen, split queen, king, split king, California king, split California king | Massager: Yes | Mattress included: No | Trial period: None | Warranty: 25 years
Best for: People with back pain
Couples who snore
Those who want their bed set up for them upon delivery
Skip if: You're looking for more advanced features, like sleep tracking and AI tech
You need a frame that supports more than 650 pounds total
Setting up the Tempur-Ergo Power Base was incredibly straightforward. The bed arrives as one piece that's simply folded in half; you just have to attach the legs and the retainer bar (at the foot of the bed) and connect the power supply and power cord, then plug it into a nearby outlet. Note, however, that the bed is heavy— so it's definitely a two-person job if you decide to do it yourself. Tempur-Pedic does offer the option for free in-home setup, but because I had to disassemble my previous bed frame and was also waiting on a new mattress, I opted to set it up myself.
The Tempur-Ergo Adjustable Power Base is easy to set up, and it arrives in one piece that looks like ... More this underneath. Emmy Favilla For Forbes
Installing the legs was very simple and done by threading the leg into the frame and tightening it by hand. You can customize the bed's height to four different options, which I appreciated: Each leg is basically a sort of cone shape split into four 3-inch segments, and you can use one piece or stack up to all four. It's definitely worth measuring how high off the ground you prefer your bed to be before installing the legs. I initially was a little off-base by just eyeballing the legs and estimating which length would work best, which meant we had to flip over the base one more time (again, it's heavy—so this was not ideal), read just the legs and then flip it back.
My first impression of this base was that it's incredibly sturdy, and while you can incorporate it into most modern existing bed frames, I use this base on its own. It also seems very straightforward to add on a headboard of your choice if you prefer to, but note that headboard brackets are an optional accessory and not included with the bed. My mattress has had no issues moving around on the base—the retainer bar at the foot keeps it in place—despite sharing my bed with another human and two large-breed dogs who jump on and off the bed regularly.
The retainer bar at the foot of the bed keeps your mattress in place. Emmy Favilla For Forbes
Like most adjustable beds, the Tempur-Ergo Power Base gives you the ability to customize the angle of elevation at the head and foot via an extremely intuitive remote control. There's also a 'zero-gravity' setting, which elevates both the head and foot of the bed significantly in order to evenly distribute your weight; it's intended to simulate a feeling of weightlessness and provide pressure relief and alleviate pain.
While using this setting while relaxing in bed is very comfortable, I don't sleep with the bed set to this zero gravity, as I'm primarily a side sleeper and personally don't find it ideal for that position. However, if you're a back sleeper and don't change positions often throughout the night, you might find this setting beneficial. (Note, of course, that although this adjustable bed is designed to help alleviate pain and other health issues, always consult your doctor first if you suffer from chronic pain or sleep apnea.) I do enjoy relaxing while reading or watching TV with my legs and feet elevated, but I typically return the foot of the bed close to its default position before going to sleep. Lumbar Support
This base is designed with a lumbar reinforcement bar that sits in the lower third of the top half of the bed, intended to provide additional support (for all sleeping positions). This is a great feature for those who experience regular back pain, anyone over 250 pounds or those who have a mattress that may be too soft for their needs. It can be raised up to six inches to accommodate your preferences, using the accompanying remote control. As someone prone to regular back aches, I do find that sleeping on my back with the addition of this support (raised only slightly) increases my comfort, but note that when you elevate this, it raises across the entire bed—so if you share your bed with a partner, you'll want to determine what's best for the both of you. (This is not the case, however, for a split king or split California king model.) Under-Bed Light
The first time I experienced an under-bed light, I was staying at a high-end hotel and thought it was such a nifty feature for anyone who gets up in the middle of the night and needs just enough light to, say, navigate their way to the bathroom without waking up their partner. Having it on my own bed is a really nice bonus, especially because I have two dogs who sometimes wake me up in the middle of the night to go out to relieve themselves in our yard. Given that my blackout curtains keep my bedroom pretty much pitch black during the night, if my phone isn't immediately within reach, I can turn on this setting using the remote to provide some light without disturbing my husband's sleep.
The under-bed lighting feature provides just enough light if you have to get up in the middle of the ... More night. Emmy Favilla for Forbes Massage
Many modern adjustable bases include a massage feature, and while I was admittedly (and perhaps embarrassingly) most excited about this functionality, it's probably the one I use least. The Tempur-Ergo Power Base incorporates a vibrating massage feature with two intensity levels focused on the lower back. The next model up, the Tempur-Ergo Smart Base, enhances this massage feature with three intensities targeting both the head and foot of the bed. At the top of the line, the highest-end model introduces a more advanced massage system that uses sound waves to transmit vibrations throughout the entire mattress.
Because I've never used an adjustable base or experienced a bed with massage capabilities, I was surprisingly impressed by how much I could feel the vibrations even through my 13-inch mattress. While it's no match for an actual massage, of course, it's a relatively enjoyable sensation, especially if you have some aches and pains in your back or are just tired after a long day. USB Ports
There are two USB ports, on either side of the base, so you can easily charge your devices without needing to leave the bed.
The Tempur-Ergo Adjustable Power Base remote control is very intuitive to use. Emmy Favilla for Forbes Remote
Everything is controlled using the included remote, which is extremely intuitive. In addition to the head and foot elevation, zero-gravity, massage, under-bed lighting and lumbar support controls, there is also a child-lock button (which you hold down for three seconds to lock), a star to program your favorite presets, an anti-snore preset position (which elevates the head slightly; I sleep using this position) and a button to reset everything to flat. About Tempur-Pedic Adjustable Beds
The Tempur-Ergo Power Base is one of four bases that Tempur-Pedic offers; it's the second-tier model in the line, with more features than the standard Ease Power Base ($999 for a queen), which provides only the option to adjust the head and foot of the bed. If that's all you're looking for in an adjustable base, that may be an adequate bed for you.
A split-king adjustable base and mattress gives two people who share a bed the most customizable ... More experience. Tempur-Pedic
Conversely, if you're seeking more advanced sleep-tracking capabilities, Tempur-Pedic also offers two smart bases: the Tempur-Ergo Smart Base ($1,999 for a queen) and the Tempur-Ergo ProSmart Base ($2,599 for a queen), the most premium model in the line. The smart bases provide a host of sleep insights accessible via an accompanying app as well as a 'Snore Response' feature, which automatically raises the head of the bed by 12 degrees when it senses snoring, plus more advanced massage functionalities. The ProSmart Base also has something called 'SoundScape Mode,' which allows you to hear and feel sound through the mattress for supreme relaxation. Final Thoughts On The Tempur-Pedic Tempur-Ergo Power Base
While this base doesn't incorporate fancy AI features, an automatic adjustment in response to snoring or more advanced massage capabilities, like the two smart bases in its line do, the Tempur-Ergo Adjustable Power Base has more than enough extras to truly upgrade anyone's sleep setup. Sleeping with our heads slightly elevated has proven to be noticeably helpful in minimizing my husband's snoring (the loudly snoring dogs we share the bed with, however, are another story); as a notoriously light sleeper, I'm frequently jostled awake when he snores, and since using this base, it has rarely happened. Either I'm sleeping more comfortably or he is snoring less, but either way, I'll take that as a win.
The Tempur-Ergo Adjustable Power Base can be used on its own or with most modern bed frames. Tempur-Pedic
I also appreciate the 'nice to haves,' like under-bed lighting, the zero-gravity feature, the additional lumbar support and the two massage intensities, which I think are well worth the base's $1,599 price tag for a queen size. If you're seeking a no-frills option that simply allows you to elevate the head and foot of your bed, though, and looking to save a few hundred dollars, the Tempur-Pedic Ease Power Base may be just as welcome an addition to your bedroom. These durable bases are built to last and come backed by a generous 25-year limited warranty. Keep in mind, however, that they do not have trial periods and cannot be returned, so it's important to figure out which of the four models best suits your needs before making a purchase. Why Trust Forbes Vetted
This review is overseen by Forbes Vetted's experienced and sleep coach–certified sleep team, who leverage nearly a decade of experience testing over 200 mattresses as well as bases, bed frames and other sleep accessories to publish a large library of mattress and sleep guides . I'm Emmy Favilla, Forbes Vetted's managing editor and a media industry veteran of over two decades. I've spent the last eight years of my career professionally testing, researching and reviewing a variety of consumer products. My coverage over the years has spanned sleep and mattress, home and kitchen, pet products and other topics. I have also personally tested dozens of mattresses alongside our mattress and sleep editors to determine the best ones for various needs.
This review was edited by senior mattress and sleep editor Bridget Chapman , who leads our sleep team alongside editor McKenzie Dillon . Chapman and Dillon recently published an update to our guide to the best adjustable beds and they are also certified sleep science coaches who continuously stay on top of the latest developments in the industry.
, who leads our sleep team alongside editor . Chapman and Dillon recently published an update to our guide to the best adjustable beds and they are also certified sleep science coaches who continuously stay on top of the latest developments in the industry. We routinely update reviews with additional insights derived from our long-term testing experiences as well as to ensure all information remains accurate and up-to-date. This review was published and last updated in July 2025.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

Yahoo

time24 minutes ago

  • Yahoo

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be discussed with global health authorities for potential regulatory filings NEW YORK & TOKYO, August 12, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. At the first interim efficacy analysis, the trial demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS), the study's primary endpoint, and overall survival (OS), a key secondary endpoint, with neoadjuvant and adjuvant PADCEV plus KEYTRUDA versus surgery alone. An additional secondary endpoint of pathologic complete response (pCR) rate was also met. Christof Vulsteke, M.D., Ph.D., Head of Integrated Cancer Center Ghent (IKG, Belgium) and Clinical Trial Unit Oncology Ghent and EV-303 principal investigator"Patients with muscle-invasive bladder cancer who are ineligible for cisplatin treatment have not seen a significant treatment advance in decades and face high rates of disease recurrence and a poor prognosis, even after having their bladder removed. These EV-303 study results mark the first time a systemic treatment approach, used before and after surgery, significantly extended survival over standard-of-care surgery in this population, demonstrating the potential of this combination to address a critical unmet patient need." The trial is continuing to evaluate the secondary EFS, OS and pCR rate endpoints for neoadjuvant and adjuvant KEYTRUDA versus surgery alone as they continue to mature. The safety profiles for PADCEV plus KEYTRUDA and KEYTRUDA monotherapy were consistent with the known profiles of each treatment regimen. Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Head of Oncology Development, Astellas"These results from EV-303 represent a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer, demonstrating the potential of PADCEV in combination with KEYTRUDA when used before and after surgery as a new standard of care. We look forward to presenting further details on these data at an upcoming medical congress." Bladder cancer is the ninth most common cancer worldwide, diagnosed in more than 614,000 patients each year globally.i MIBC represents approximately 30% of all bladder cancer The standard treatment for patients with MIBC is neoadjuvant cisplatin-based chemotherapy followed by surgery, which has been shown to prolong However, up to half of patients with MIBC are not eligible to receive cisplatin and face limited treatment options, typically undergoing surgery Johanna Bendell, M.D., Oncology Chief Development Officer, Pfizer"PADCEV plus KEYTRUDA has already changed the treatment paradigm for patients with locally advanced or metastatic urothelial cancer as standard of care. These latest results underscore the practice-changing potential of this combination in earlier stages of bladder cancer, where it has the potential to improve outcomes for even more patients. Thank you to the patients and investigators who participated in this trial." Results will be submitted for presentation at an upcoming medical congress and will be discussed with global health authorities for potential regulatory filings. Neoadjuvant and adjuvant PADCEV plus KEYTRUDA is also being evaluated in cisplatin-eligible patients with MIBC in the EV-304 Phase 3 clinical trial (also known as KEYNOTE-B15). About the EV-303 TrialThe EV-303 trial is an ongoing, open-label, randomized, three-arm, controlled, Phase 3 study evaluating neoadjuvant and adjuvant PADCEV in combination with KEYTRUDA or neoadjuvant and adjuvant KEYTRUDA versus surgery alone in patients with MIBC who are either not eligible for or declined cisplatin-based chemotherapy. Patients were randomized to receive either neoadjuvant and adjuvant KEYTRUDA (arm A), surgery alone (arm B) or neoadjuvant and adjuvant PADCEV in combination with KEYTRUDA (arm C).iv The primary endpoint of this trial is EFS between arm C versus arm B, defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes radical cystectomy (RC) surgery or failure to undergo RC surgery in participants with residual disease, gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy or death due to any cause. Key secondary endpoints include OS and pCR rate between arm C and arm B, as well as EFS, OS and pCR rate between arm A and arm For more information on the global EV-303 trial, go to About PADCEV™ (enfortumab vedotin)PADCEV™ (enfortumab vedotin) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.v Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4-expressing cells, followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).vi PADCEV plus KEYTRUDA is approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) regardless of cisplatin eligibility in the United States, the European Union, Japan and a number of other countries around the world. PADCEV is also approved as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of PADCEV® (enfortumab vedotin-ejfv) U.S. Indication & Important Safety Information BOXED WARNING: SERIOUS SKIN REACTIONS PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later. Closely monitor patients for skin reactions. Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions. Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions. IndicationPADCEV®, in combination with pembrolizumab, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who: have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. PADCEV Important Safety Information Warnings and Precautions Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV. SJS and TEN occurred predominantly during the first cycle of treatment but may occur later. Skin reactions occurred in 70% (all grades) of the 564 patients treated with PADCEV in combination with pembrolizumab in clinical trials. When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate compared to PADCEV as a single agent. The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash. Grade 3-4 skin reactions occurred in 17% of patients (Grade 3: 16%, Grade 4: 1%), including maculo-papular rash, bullous dermatitis, dermatitis, exfoliative dermatitis, pemphigoid, rash, erythematous rash, macular rash, and papular rash. A fatal reaction of bullous dermatitis occurred in one patient (0.2%). The median time to onset of severe skin reactions was 1.7 months (range: 0.1 to 17.2 months). Skin reactions led to discontinuation of PADCEV in 6% of patients. Skin reactions occurred in 58% (all grades) of the 720 patients treated with PADCEV as a single agent in clinical trials. Twenty-three percent (23%) of patients had maculo-papular rash and 34% had pruritus. Grade 3-4 skin reactions occurred in 14% of patients, including maculo-papular rash, erythematous rash, rash or drug eruption, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, and palmar-plantar erythrodysesthesia. The median time to onset of severe skin reactions was 0.6 months (range: 0.1 to 8 months). Among patients experiencing a skin reaction leading to dose interruption who then restarted PADCEV (n=75), 24% of patients restarting at the same dose and 24% of patients restarting at a reduced dose experienced recurrent severe skin reactions. Skin reactions led to discontinuation of PADCEV in 3.1% of patients. Monitor patients closely throughout treatment for skin reactions. Consider topical corticosteroids and antihistamines, as clinically indicated. For persistent or recurrent Grade 2 skin reactions, consider withholding PADCEV until Grade ≤1. Withhold PADCEV and refer for specialized care for suspected SJS, TEN or for Grade 3 skin reactions. Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions. Hyperglycemia and diabetic ketoacidosis (DKA), including fatal events, occurred in patients with and without pre-existing diabetes mellitus, treated with PADCEV. Patients with baseline hemoglobin A1C ≥8% were excluded from clinical trials. In clinical trials of PADCEV as a single agent, 17% of the 720 patients treated with PADCEV developed hyperglycemia of any grade; 7% of patients developed Grade 3-4 hyperglycemia (Grade 3: 6.5%, Grade 4: 0.6%). Fatal events of hyperglycemia and DKA occurred in one patient each (0.1%). The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. The median time to onset of hyperglycemia was 0.5 months (range: 0 to 20 months). Hyperglycemia led to discontinuation of PADCEV in 0.7% of patients. Five percent (5%) of patients required initiation of insulin therapy for treatment of hyperglycemia. Of the patients who initiated insulin therapy for treatment of hyperglycemia, 66% (23/35) discontinued insulin at the time of last evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV. Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated with PADCEV. When PADCEV was given in combination with pembrolizumab, 10% of the 564 patients treated with combination therapy had pneumonitis/ILD of any grade and 4% had Grade 3-4. A fatal event of pneumonitis/ILD occurred in two patients (0.4%). The incidence of pneumonitis/ILD, including severe events, occurred at a higher rate when PADCEV was given in combination with pembrolizumab compared to PADCEV as a single agent. The median time to onset of any grade pneumonitis/ILD was 4 months (range: 0.3 to 26 months). In clinical trials of PADCEV as a single agent, 3% of the 720 patients treated with PADCEV had pneumonitis/ILD of any grade and 0.8% had Grade 3-4. The median time to onset of any grade pneumonitis/ILD was 2.9 months (range: 0.6 to 6 months). Monitor patients for signs and symptoms indicative of pneumonitis/ILD such as hypoxia, cough, dyspnea or interstitial infiltrates on radiologic exams. Evaluate and exclude infectious, neoplastic and other causes for such signs and symptoms through appropriate investigations. Withhold PADCEV for patients who develop Grade 2 pneumonitis/ILD and consider dose reduction. Permanently discontinue PADCEV in all patients with Grade 3 or 4 pneumonitis/ILD. Peripheral neuropathy (PN) When PADCEV was given in combination with pembrolizumab, 67% of the 564 patients treated with combination therapy had PN of any grade, 36% had Grade 2 neuropathy, and 7% had Grade 3 neuropathy. The incidence of PN occurred at a higher rate when PADCEV was given in combination with pembrolizumab compared to PADCEV as a single agent. The median time to onset of Grade ≥2 PN was 6 months (range: 0.3 to 25 months). PN occurred in 53% of the 720 patients treated with PADCEV as a single agent in clinical trials including 38% with sensory neuropathy, 8% with muscular weakness and 7% with motor neuropathy. Thirty percent of patients experienced Grade 2 reactions and 5% experienced Grade 3-4 reactions. PN occurred in patients treated with PADCEV with or without preexisting PN. The median time to onset of Grade ≥2 PN was 4.9 months (range: 0.1 to 20 months). Neuropathy led to treatment discontinuation in 6% of patients. Monitor patients for symptoms of new or worsening PN and consider dose interruption or dose reduction of PADCEV when PN occurs. Permanently discontinue PADCEV in patients who develop Grade ≥3 PN. Ocular disorders were reported in 40% of the 384 patients treated with PADCEV as a single agent in clinical trials in which ophthalmologic exams were scheduled. The majority of these events involved the cornea and included events associated with dry eye such as keratitis, blurred vision, increased lacrimation, conjunctivitis, limbal stem cell deficiency, and keratopathy. Dry eye symptoms occurred in 30% of patients, and blurred vision occurred in 10% of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.7 months (range: 0 to 30.6 months). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders. Infusion site extravasation Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 720 patients treated with PADCEV as a single agent in clinical trials, 1% of patients experienced skin and soft tissue reactions, including 0.3% who experienced Grade 3-4 reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. Two patients (0.3%) developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions. Embryo-fetal toxicity PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose. ADVERSE REACTIONS Most common adverse reactions, including laboratory abnormalities (≥20%) (PADCEV in combination with pembrolizumab)Increased aspartate aminotransferase (AST), increased creatinine, rash, increased glucose, PN, increased lipase, decreased lymphocytes, increased alanine aminotransferase (ALT), decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased appetite, increased urate, decreased neutrophils, decreased potassium, dry eye, nausea, constipation, increased potassium, dysgeusia, urinary tract infection and decreased platelets. Most common adverse reactions, including laboratory abnormalities (≥20%) (PADCEV monotherapy)Increased glucose, increased AST, decreased lymphocytes, increased creatinine, rash, fatigue, PN, decreased albumin, decreased hemoglobin, alopecia, decreased appetite, decreased neutrophils, decreased sodium, increased ALT, decreased phosphate, diarrhea, nausea, pruritus, increased urate, dry eye, dysgeusia, constipation, increased lipase, decreased weight, decreased platelets, abdominal pain, dry skin. EV-302 Study: 440 patients with previously untreated la/mUC (PADCEV in combination with pembrolizumab)Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab. The most common serious adverse reactions (≥2%) were rash (6%), acute kidney injury (5%), pneumonitis/ILD (4.5%), urinary tract infection (3.6%), diarrhea (3.2%), pneumonia (2.3%), pyrexia (2%), and hyperglycemia (2%). Fatal adverse reactions occurred in 3.9% of patients treated with PADCEV in combination with pembrolizumab including acute respiratory failure (0.7%), pneumonia (0.5%), and pneumonitis/ILD (0.2%). Adverse reactions leading to discontinuation of PADCEV occurred in 35% of patients. The most common adverse reactions (≥2%) leading to discontinuation of PADCEV were PN (15%), rash (4.1%) and pneumonitis/ILD (2.3%). Adverse reactions leading to dose interruption of PADCEV occurred in 73% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were PN (22%), rash (16%), COVID‑19 (10%), diarrhea (5%), pneumonitis/ILD (4.8%), fatigue (3.9%), hyperglycemia (3.6%), increased ALT (3%) and pruritus (2.5%). Adverse reactions leading to dose reduction of PADCEV occurred in 42% of patients. The most common adverse reactions (≥2%) leading to dose reduction of PADCEV were rash (16%), PN (13%) and fatigue (2.7%). EV-103 Study: 121 patients with previously untreated la/mUC who were not eligible for cisplatin-containing chemotherapy (PADCEV in combination with pembrolizumab)Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab; the most common (≥2%) were acute kidney injury (7%), urinary tract infection (7%), urosepsis (5%), sepsis (3.3%), pneumonia (3.3%), hematuria (3.3%), pneumonitis/ILD (3.3%), urinary retention (2.5%), diarrhea (2.5%), myasthenia gravis (2.5%), myositis (2.5%), anemia (2.5%), and hypotension (2.5%). Fatal adverse reactions occurred in 5% of patients treated with PADCEV in combination with pembrolizumab, including sepsis (1.6%), bullous dermatitis (0.8%), myasthenia gravis (0.8%), and pneumonitis/ILD (0.8%). Adverse reactions leading to discontinuation of PADCEV occurred in 36% of patients; the most common (≥2%) were PN (20%) and rash (6%). Adverse reactions leading to dose interruption of PADCEV occurred in 69% of patients; the most common (≥2%) were PN (18%), rash (12%), increased lipase (6%), pneumonitis/ILD (6%), diarrhea (4.1%), acute kidney injury (3.3%), increased ALT (3.3%), fatigue (3.3%), neutropenia (3.3%), urinary tract infection (3.3%), increased amylase (2.5%), anemia (2.5%), COVID‑19 (2.5%), hyperglycemia (2.5%), and hypotension (2.5%). Adverse reactions leading to dose reduction of PADCEV occurred in 45% of patients; the most common (≥2%) were PN (17%), rash (12%), fatigue (5%), neutropenia (5%), and diarrhea (4.1%). EV-301 Study: 296 patients previously treated with a PD-1/L1 inhibitor and platinum-based chemotherapy (PADCEV monotherapy)Serious adverse reactions occurred in 47% of patients treated with PADCEV; the most common (≥2%) were urinary tract infection, acute kidney injury (7% each), and pneumonia (5%). Fatal adverse reactions occurred in 3% of patients, including multiorgan dysfunction (1%), hepatic dysfunction, septic shock, hyperglycemia, pneumonitis/ILD, and pelvic abscess (0.3% each). Adverse reactions leading to discontinuation occurred in 17% of patients; the most common (≥2%) were PN (5%) and rash (4%). Adverse reactions leading to dose interruption occurred in 61% of patients; the most common (≥4%) were PN (23%), rash (11%), and fatigue (9%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common (≥2%) were PN (10%), rash (8%), decreased appetite, and fatigue (3% each). EV-201, Cohort 2 Study: 89 patients previously treated with a PD-1/L1 inhibitor and not eligible for cisplatin-based chemotherapy (PADCEV monotherapy)Serious adverse reactions occurred in 39% of patients treated with PADCEV; the most common (≥3%) were pneumonia, sepsis, and diarrhea (5% each). Fatal adverse reactions occurred in 8% of patients, including acute kidney injury (2.2%), metabolic acidosis, sepsis, multiorgan dysfunction, pneumonia, and pneumonitis/ILD (1.1% each). Adverse reactions leading to discontinuation occurred in 20% of patients; the most common (≥2%) was PN (7%). Adverse reactions leading to dose interruption occurred in 60% of patients; the most common (≥3%) were PN (19%), rash (9%), fatigue (8%), diarrhea (5%), increased AST, and hyperglycemia (3% each). Adverse reactions leading to dose reduction occurred in 49% of patients; the most common (≥3%) were PN (19%), rash (11%), and fatigue (7%). DRUG INTERACTIONSEffects of other drugs on PADCEV (Dual P-gp and Strong CYP3A4 Inhibitors)Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated monomethyl auristatin E exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors. SPECIFIC POPULATIONSLactation Advise lactating women not to breastfeed during treatment with PADCEV and for 3 weeks after the last dose. Hepatic impairment Avoid the use of PADCEV in patients with moderate or severe hepatic impairment. For more information, please see the U.S. full Prescribing Information including BOXED WARNING for PADCEV here. About AstellasAstellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at About Pfizer OncologyAt Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About the Pfizer, Astellas and Merck CollaborationSeagen and Astellas previously entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's KEYTRUDA™ (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). Astellas Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. Pfizer Disclosure NoticeThe information contained in this release is as of August 12, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer Oncology and PADCEV™(enfortumab vedotin) in combination with pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer, including their potential benefits, and plans to submit results from the Phase 3 EV-303 clinical trial for presentation at an upcoming medical congress and to share the Phase 3 EV-303 clinical trial results with the appropriate regulatory authorities to explore potential regulatory filings that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of PADCEV; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed with regulatory authorities in particular jurisdictions for any potential indication for PADCEV with pembrolizumab or as a single agent; whether and when any applications that may be pending or filed for PADCEV with pembrolizumab or as a single agent may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether PADCEV with pembrolizumab or as a single agent will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of PADCEV with pembrolizumab or as a single agent; whether the collaboration between Pfizer, Astellas and Merck will be successful; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer's business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and _________________________ i World Bladder Cancer Patient Coalition. GLOBOCAN 2022: Bladder cancer 9th most common worldwide. Accessed August 11, 2025. Available at: ii Bladder Cancer Awareness Network. What is Muscle Invasive Bladder Cancer? Accessed August 11, 2025. Available at: iii Esteban-Villarrubia J, Torres-Jiménez J, Bueno-Bravo C, García-Mondaray R, Subiela JD, Gajate P. Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer. Cancers (Basel). 2023 Jan 17;15(3):566. doi: 10.3390/cancers15030566. PMID: 36765525; PMCID: PMC9913718. iv National Institute of Health. National Library of Medicine. Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/​KEYNOTE-905/​EV-303. identifier: NCT03924895. Published July 24, 2019. Updated June 17, 2025. Accessed August 11, 2025. Available at: v Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 2016;76(10):3003-13. vi PADCEV [package insert]. Northbrook, IL: Astellas Pharma US, Inc. View source version on Contacts Pfizer Media Contact:PfizerMediaRelations@ +1-212-733-1226Pfizer Investor Contact:IR@ +1-212-733-4848Astellas Contact:Garrett Corporate Communications+81-3-3244-3202 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Help Patients Navigate Viral Seed Oil Claims
Help Patients Navigate Viral Seed Oil Claims

Medscape

time25 minutes ago

  • Medscape

Help Patients Navigate Viral Seed Oil Claims

Your patients may come to you with questions about consuming seed oils, particularly because they've been trending on social media. In recent months, online claims have included references to the 'hateful eight' of seed oils: canola, corn, cottonseed, safflower, soy, sunflower, rice bran, and grapeseed. Among the claims: Seed oils increase inflammation, obesity, and even brain fog. But the truth is, as usual, more complicated, and your patients may not realize that seed oils can indeed be part of a healthy diet. Here's how to prepare for the questions. Caroline Susie, RDN, LD 'Oils are a fat,' said Caroline Susie, RDN, LD, Dallas-based spokesperson for the Academy of Nutrition and Dietetics. Because these cooking oils are inexpensive and have a high smoke point, they are commonly used in processed foods, restaurant frying, and home cooking. She said when discussing seed oils with patients, it's best to focus on the overall pattern of their diets. 'Fried foods, no matter what oil is used, are high in calories and fat. Excess calories and fat in the diet can contribute to weight gain,' she said. How to Better Explain the Complexity of Seed Oils Seed oils are naturally occurring in different foods like eggs, almonds, tofu, and chia seeds. 'They are not necessarily bad in their natural form — it's when they are refined that they become this ultra-processed oil, and when eaten in high amounts, they increase inflammation in the body and ultimately lead to chronic disease over time, including obesity,' said Rebecca Jones, MS, a registered dietitian and bariatric coordinator for Novant Health Triad Region in North Carolina. But are they unhealthy, as social media posts would have your patients believe? Their composition plays a role. 'They are not saturated fats. Seed oils typically are polyunsaturated fats,' Jones said. 'In small amounts in their whole food state, they can be beneficial for heart health and disease. It's when they are refined and eaten in large quantities that they are unhealthy.' She said research shows that, on average, we eat a 10 to 1 ratio of seed oils (or omega-6 fatty acids) to omega-3 fatty acids. The goal would be to balance these two as much as possible, Jones said. In the broader scope, a study revealed that individuals who swapped about 10 g of butter with plant-based oils such as canola, soybean, or olive oil cut premature death by 17%. Who Should Avoid Using Seed Oils? For patients at risk for heart disease or diabetes, or a person who is dealing with obesity, trying to choose more whole food sources of these omega-6 fatty acids vs the ultra-processed versions like chips, snack cakes, and fast foods is preferable and healthier, said Jones. 'Leaning into a healthy diet and eating a wide variety of whole foods is going to be helpful to anyone concerned about chronic disease,' she added. When discussing seed oils with your patients, you can suggest moderation. 'If they are cooking at home and they're using a little bit of canola oil to roast your vegetables or something like that, that's certainly different than getting a fast-food meal fried in canola oil. Everything in moderation is key,' said Jones. How to Cut Back and What Are Better Choices? If patients are particularly concerned, you could suggest swapping seed oil for a healthier choice. 'If they are cooking at home and using canola oil, using avocado oil or olive oil is going to be a better choice,' said Jones. Jones also suggests limiting ultra-processed snacks and fast foods. 'That's where most of our consumption of seed oils is coming from in the US. It's all about convenience for people — we are way overscheduled, and we are way too busy. It's more convenient.'

American Lung Association Urges Schools to Test for Radon to Protect Students and Staff
American Lung Association Urges Schools to Test for Radon to Protect Students and Staff

Associated Press

time25 minutes ago

  • Associated Press

American Lung Association Urges Schools to Test for Radon to Protect Students and Staff

CHICAGO, Aug. 12, 2025 /PRNewswire/ -- With more than 55 million children and 6 million adults spending their days in K–12 school buildings across the country, the American Lung Association is urging school administrators to prioritize indoor air quality by testing for radon, a leading cause of lung cancer and a hidden threat in many schools. Radon is a naturally occurring, odorless, tasteless, and colorless radioactive gas that can accumulate indoors, including in schools. It is the second leading cause of lung cancer in the United States and is responsible for approximately 21,000 deaths annually. The only way to determine if a school has elevated levels of radon is through testing. 'Every child deserves a healthy place to learn, and every educator deserves a healthy place to work,' said Harold Wimmer, President and CEO of the American Lung Association. 'Radon is a cancer-causing gas that can accumulate inside schools without anyone knowing. The good news is that testing for radon is simple and affordable—and schools can take action to fix the problem if levels are high.' Indoor air quality plays a critical role in both student learning and staff health. Americans spend about 90% of their time indoors, where air pollution levels can be two to five times higher than outside. Poor air quality in schools has been linked to reduced academic performance, increased absenteeism, and a higher risk of respiratory illnesses and other serious health conditions. Radon can enter buildings through cracks in floors, walls, and foundations. There is no known safe level of radon exposure. The Environmental Protection Agency (EPA) recommends taking action to reduce radon if radon levels are at or above 4.0 picocuries per liter (pCi/L) and considering action for levels between 2.0 and 4.0 pCi/L. In many states, school officials can be trained to perform radon testing or licensed professionals can be hired to do the testing. Radon testing guidance for schools is available here. The American Lung Association is calling on all school districts to test their facilities and take mitigation steps if needed to protect the health and well-being of students, faculty, and staff. Learn more about radon testing in schools and find resources at About the American Lung Association The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Platinum-Level GuideStar Member, call 1-800-LUNGUSA (1-800-586-4872) or visit: To support the work of the American Lung Association, find a local event at View original content to download multimedia: SOURCE American Lung Association

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store